Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Blood transfusion · people with preoperative anaemia awaiting major surgery
Iron therapy showed no clear difference in proportion of participants who received a blood transfusion compared with placebo, no treatment or standard care (low certainty).
1 finding from 1 review
Quality of life (validated questionnaire) · people with preoperative anaemia awaiting major surgery
1 finding from 1 review
Haemoglobin (g/dL) · people with preoperative anaemia awaiting major surgery
Iron therapy showed no clear difference in haemoglobin levels at end of preoperative treatment (g/dL) compared with placebo, no treatment or standard care (low certainty).
2 findings from 1 review
Ferritin (µg/L) · people with preoperative anaemia awaiting major surgery
Iron therapy may leads to higher ferritin at the end of preoperative treatment (ng/mL) compared with placebo, no treatment or standard care (low certainty).
1 finding from 1 review
Nausea severity · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
1 finding from 1 review
Nausea duration (nausea‐free at end of treatment) Measured by participant self‐report or medical or nursing observation · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
It is very uncertain whether aromatherapy changes nausea duration (nausea‐free at end of treatment) Assessed by… compared with placebo (very low certainty).
1 finding from 1 review
Rescue antiemetic · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
Aromatherapy may leads to lower proportion requiring rescue antiemetics Assessed by numbers of… compared with placebo (low certainty).
1 finding from 1 review
Patient satisfaction with treatment Measured by a validated scale · adults and children having any type of surgical procedure under general anaesthesia, regional anaesthesia or sedation, as hospital…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR
1 finding from 1 review
Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR
1 finding from 1 review
Quality of life · children and adults with SCD and PSR
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR
1 finding from 1 review
Occurence of vitreous haemorrhage · children and adults with SCD and PSR
1 finding from 1 review
Adverse effects · children and adults with SCD and PSR
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found